New Trial With Longer Liver Elevation Needed For Iclaprim, US FDA Tells Motif Bio
Longer follow-up is part of regulatory path forward, the struggling antibiotics firm says after meeting with US FDA to discuss complete response letter.
You may also be interested in...
The UK biotech is in dire need of further funding after US regulators requested an additional clinical trial for its much-delayed skin infection antibiotic.
The latest drug development news and highlights from our US FDA Performance Tracker.
Positive data from a second Phase III trial sets up Motif Bio for an NDA filing by the end of the year for novel antibiotic iclaprim – but success for the product has been a long time coming.